Science for Life
grid
Home
About IHVR
Partnerships
Research
Scientists
Education
Biotechnology
News
Contact Us

Faculty

Tülin U. Morçöl, PhD

Prior to founding CaPtivate Pharmaceuticals in 2011, Dr. Morçöl worked for BioSante Pharmaceuticals, Inc. for 13 years, first as Associate Director of Research and Development and then Director of Preclinical Development.  During her tenure at BioSante, she focused on developing formulation strategies for therapeutic drugs and vaccines using company’s CaP nanoparticle (CaP) technology for non-invasive administration, and developing processes for large scale-GMP manufacturing of CaP nanoparticles. She expanded the applications of CaP-based technologies to selectively isolating recombinant proteins from the milk of transgenic livestock and developing formulations for esthetic medicine. In 2007 BioSante licensed the exclusive world-wide rights for the use of CaP as facial filler to Medical Aesthetics Technology Corporation (MATC). In 2006 she led the relocation of BioSante’s R&D facilities from Atlanta, GA, to Pennsylvania Biotechnology Center in Doylestown, PA, and the creation of BioSante Pennsylvania Research Laboratory. Before joining BioSante, she worked at the Morehouse School of Medicine (MSM), Department of Neurosciences, Atlanta, GA, for four years. At MSM, she studied the neurodegenerative diseases of the brain. Before moving to USA, Dr. Morçöl worked as a scientist for the Turkish Atomic Energy Agency for 5 years. She received her BS and MS degrees in Chemical Engineering in Turkey.  She earned her PhD in Biochemical Engineering from Virginia Polytechnic Institute and State University in 1992. At Virginia Tech, she studied under the mentorship of Dr. William H. Velander and as a member of his Transgenic Animal Research Team. The team’s most pioneering achievement has been the generation of the world’s first transgenically-produced farm animal, the pig known as Genie, expressing the human plasma protein C in her milk. Her current research interest includes the development of new or improved vaccines and alternative routes of administration through CaPtivate’s proprietary CaP nanoparticle vaccine adjuvant. 

 

Calendar
Related Links
Job Opportunities
Location
corner